Imugene welcomes dosing of first patient in nextHERIZON Phase 2 clinical trial

Imugene CEO and managing director Leslie Chong chats with Andrew Scott from Proactive about the first patient being dosed in the nextHERIZON Phase 2 clinical trial for HER-Vaxx. Chong discusses the positive results already seen from HER-Vaxx as well as in the phase 1 Vaxinia trial. The company has also appointed a industry and drug development expert Dr Jakob Dupont as a non executive director.
#Imuguene #asx #proactiveaustralia #clinicaltrial

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews